T1	Participants 79 108	metastatic colorectal cancer.
T2	Participants 225 274	patients with metastatic colorectal cancer (mCRC)
T3	Participants 461 675	17 polymorphisms in genes encoding drug targets, pathway molecules and detoxification enzymes was analyzed in 279 previously untreated mCRC patients treated with capecitabine, oxaliplatin and bevacizumab (CAPOX-B).
T4	Participants 1469 1483	mCRC patients.
